Asthma management in low and middle income countries: case for change
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Asthma is the most common noncommunicable disease in children, and among the most common in adults. The great majority of people with asthma live in low and middle income countries (LMICs), which have disproportionately high asthma-related morbidity and mortality. Essential inhaled medications, particularly those containing inhaled corticosteroids (ICS), are often unavailable or unaffordable, and this explains much of the global burden of preventable asthma morbidity and mortality. Guidelines developed for LMICs are generally based on the outdated assumption that patients with asthma symptoms <1–3 times per week do not need (or benefit from) ICS. Even when ICS are prescribed, many patients manage their asthma with oral or inhaled short-acting β 2-agonists (SABA) alone, owing to issues of availability and affordability. A single ICS–formoterol inhaler-based approach to asthma management for all severities of asthma, from mild to severe, starting at diagnosis, might overcome SABA overuse/over-reliance and reduce the burden of symptoms and severe exacerbations. However, ICS–formoterol inhalers are currently very poorly available or unaffordable in LMICs. There is a pressing need for pragmatic clinical trial evidence of the feasibility and cost-effectiveness of this and other strategies to improve asthma care in these countries. The global health inequality in asthma care that deprives so many children, adolescents and adults of healthy lives and puts them at increased risk of death, despite the availability of highly effective therapeutic approaches, is unacceptable. A World Health Assembly Resolution on universal access to affordable and effective asthma care is needed to focus attention and investment on addressing this need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223 · cited 1×
“trends in the prevalence of asthma[41, 42].”
Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries
Lee, B. W., & Detzel, P. R. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370221 · Cited by 1,668
Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430504 · Cited by 1,100 · cited 1×
“Inhaled corticosteroids reduce the risk of asthma mortality by over 50%,[66] reduce the risk of hospitalisation by 31%,[67] and reduce the risk of serious exacerbations by”
BackgroundLai, C. K. W., Beasley, R., Crane, J., Foliaki, S., Shah, J., Weiland, S., & the ISAAC Phase Three Study Group (2009) · Thorax · doi:10.1136/thx.2008.106609 · Cited by 1,068 · cited 1×
“trends in the prevalence of asthma[41, 42].”
Waljee, A. K., Rogers, M. A. M., Lin, P., Singal, A. G., Stein, J. D., Marks, R. M., Ayanian, J. Z., & Nallamothu, B. K. (2017) · BMJ · doi:10.1136/bmj.j1415 · Cited by 830 · cited 1×
“10 term adverse effects such as pneumonia and sepsis[83], and with long-term adverse effects including osteoporosis, cataract and diabetes[84].”
BackgroundKhreis, H., Kelly, C., Tate, J., Parslow, R., Lucas, K., & Nieuwenhuijsen, M. (2017) · Environment International · doi:10.1016/j.envint.2016.11.012 · Cited by 807 · cited 1×
“4 paracetamol[14, 16, 17], broad-spectrum antibiotics[14, 18, 19], allergens[20-22], obesity[14, 23, 24], air pollution[14, 25-28], and childhood respiratory infections[14, 29].”
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Pauwels, R. A., Pedersen, S., Busse, W. W., Tan, W. C., Chen, Y.-Z., Ohlsson, S. V., Ullman, A., Lamm, C. J., & O'Byrne, P. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12891-7 · Cited by 763 · cited 1×
“almost half,[68] with most of the benefit achieved with a low dose[69].”
BackgroundBurke, H., Leonardi-Bee, J., Hashim, A., Pine-Abata, H., Chen, Y., Cook, D. G., Britton, J. R., & McKeever, T. M. (2012) · Pediatrics · doi:10.1542/peds.2011-2196 · Cited by 711
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715274 · Cited by 645
Self-citation
Cited by
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
Levy, M. L., Bacharier, L. B., Bateman, E., Boulet, L.-P., Brightling, C., Buhl, R., Brusselle, G., Cruz, A. A., Drazen, J. M., Duijts, L., et al. (2023) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-023-00330-1 · Cited by 361
Self-citationThe burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study
García-Marcos, L., Asher, M. I., Pearce, N., Ellwood, E., Bissell, K., Chiang, C.-Y., El Sony, A., Ellwood, P., Marks, G. B., Mortimer, K., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02866-2021 · Cited by 224
Self-citationAgache, I., Annesi‐Maesano, I., Cecchi, L., Biagioni, B., Chung, K. F., Clot, B., D'Amato, G., Damialis, A., del Giacco, S., Dominguez‐Ortega, J., et al. (2024) · Allergy · doi:10.1111/all.16103 · Cited by 29
Allergy Testing in Lower Middle Income Countries
Gupta, N., & Mapondela, K. B. (2024) · Clinical & Experimental Allergy · doi:10.1111/cea.14443 · Cited by 3
Metadata
- Authors
- Mortimer, K., Reddel, H. K., Pitrez, P. M., & Bateman, E. D.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2022-02-24
- Volume
- 60
- Issue
- 3
- Pages
- 2103179
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4213419708
- Cited by
- 165
- References
- 107
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.